Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4063-4071

  Goldstein, Lori J ^a   Gray, Robert ^a   Badve, Sunil ^a   Childs, Barrett H ^a   Yoshizawa, Carl ^a   Rowley, Steve ^a   Shak, Steven ^a   Baehner, Frederick L ^a   Ravdin, Peter M ^a   Davidson, Nancy E ^a   Sledge, George W ^a   Perez, Edith A ^a   Shulman, Lawrence N ^a   Martino, Silvana ^a   Sparano, Joseph A ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; HORMONE RECEPTOR; TAMOXIFEN;

21 GENE ASSAY; ACCURACY; ADULT; AGED; ALGORITHM; ARTICLE; ASSAY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENOMICS; HISTOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LABORATORY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; MEDICAL ONCOLOGY; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECURRENCE; RISK; TIME FACTORS;

EID: 51649110952     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.4501     Document Type: Article

References (30)

1. Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
3. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
4. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
5. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
6. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005
7. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
8. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
9. Foekens JA, Atkins D, Zhang Y, et al: Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24:1665-1671, 2006
10. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102:3738-3743, 2005
11. Ma XJ, Hilsenbeck SG, Wang W, et al: The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611-4619, 2006
12. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
13. Dalton LW, Page DL, Dupont WD: Histologic grading of breast carcinoma: A reproducibility study. Cancer 73:2765-2770, 1994
14. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
15. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 131:18, 2007
16. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
17. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007
18. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
19. Sparano JA: TAILORx: Trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350, 2006
20. Albain K, Barlow W, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). Breast Cancer Res Treat 106, 2007 (suppl 1; abstr 10)
21. Viani GA, Afonso SL, Stefano EJ, et al: Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 7:153, 2007
22. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
23. Shen Y, Yang Y, Inoue LY, et al: Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials. J Natl Cancer Inst 97:1195-1203, 2005
24. Carlson RW, Brown E, Burstein HJ, et al: NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 4:S1-S26, 2006 (suppl)
25. Ryan PD, Goss PE: The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer. Nat Clin Pract Oncol 2:596-597, 2005
26. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
27. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
28. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
29. Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005
30. Jiang W, Freidlin B, Simon R: Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 99:1036-1043, 2007